Market Cap 929.75M
Revenue (ttm) 0.00
Net Income (ttm) -68.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 429,200
Avg Vol 401,048
Day's Range N/A - N/A
Shares Out 54.56M
Stochastic %K 89%
Beta N/A
Analysts Strong Sell
Price Target $33.00

Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 468 4219
Address:
116 Huntington Avenue, Suite 703, Boston, United States
DonCorleone77
DonCorleone77 Oct. 3 at 9:02 PM
$BCAX Bicara Therapeutics files $400M mixed securities shelf
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:18 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $DVLT $BCAX $ASNS $NUKK
0 · Reply
StockScanners
StockScanners Oct. 2 at 12:44 AM
$BCAX reached 17.38, lets go team
0 · Reply
highnihilism
highnihilism Oct. 1 at 6:28 AM
$BSY Bentley Systems Trade Count: 49 | Total $: 23 K | 90-Day Avg $: 277.4 K | Relative: 0.08 | Call $: 9.6 K | Put $: 13.5 K | % Single-Leg: 89% | % Multi-Leg: 11% | % Contingent: – $HDB HDFC Bank Trade Count: 20 | Total $: 9.8 K | 90-Day Avg $: 125.9 K | Relative: 0.08 | Call $: 9.6 K | Put $: 225 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $BCAX Bicara Therapeutics Trade Count: 35 | Total $: 10.7 K | 90-Day Avg $: 6.5 K | Relative: 1.64 | Call $: 9.6 K | Put $: 1.2 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CBRE CBRE Group Trade Count: 33 | Total $: 29.1 K | 90-Day Avg $: 189 K | Relative: 0.15 | Call $: 9.5 K | Put $: 19.5 K | % Single-Leg: 65% | % Multi-Leg: 35% | % Contingent: –
0 · Reply
StockScanners
StockScanners Oct. 1 at 2:15 AM
$BCAX reached 15.83
0 · Reply
highnihilism
highnihilism Sep. 30 at 4:30 PM
$BSY Bentley Systems | Price: 51.98 | % Chg: -0.7% | Trade Count: 49 | Total $: 23 K | 90-Day Avg $: 277.4 K | Relative: 0.08 | Call $: 9.6 K | Put $: 13.5 K | % Single-Leg: 89% | % Multi-Leg: 11% | % Contingent: – $HDB HDFC Bank | Price: 34.14 | % Chg: 0.0% | Trade Count: 20 | Total $: 9.8 K | 90-Day Avg $: 125.9 K | Relative: 0.08 | Call $: 9.6 K | Put $: 225 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $BCAX Bicara Therapeutics | Price: 13.87 | % Chg: +18.4% | Trade Count: 35 | Total $: 10.7 K | 90-Day Avg $: 6.5 K | Relative: 1.64 | Call $: 9.6 K | Put $: 1.2 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CBRE Cbre Group | Price: 158.96 | % Chg: +0.6% | Trade Count: 33 | Total $: 29.1 K | 90-Day Avg $: 189 K | Relative: 0.15 | Call $: 9.5 K | Put $: 19.5 K | % Single-Leg: 65% | % Multi-Leg: 35% | % Contingent: –
0 · Reply
StockScanners
StockScanners Sep. 30 at 1:09 AM
$BCAX keep watch if this holds above 12.80
0 · Reply
100Bandz
100Bandz Sep. 29 at 2:57 PM
$BCAX Trending...
0 · Reply
redistributeW
redistributeW Sep. 29 at 12:00 PM
$BCAX Why is Stocktwits deleting posts and not providing quotes for this company?
1 · Reply
highnihilism
highnihilism Sep. 17 at 11:51 AM
IWM: Russell 2000 → $GBTG Global Business Travel $NIC Nicolet Bankshares $DGII Digi International $HG Hamilton Insurance Group $BCAX Bicara Therapeutics
0 · Reply
Latest News on BCAX
Bicara: Innovative Precision Tumor Targeting

Apr 19, 2025, 6:22 AM EDT - 6 months ago

Bicara: Innovative Precision Tumor Targeting


DonCorleone77
DonCorleone77 Oct. 3 at 9:02 PM
$BCAX Bicara Therapeutics files $400M mixed securities shelf
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:18 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $DVLT $BCAX $ASNS $NUKK
0 · Reply
StockScanners
StockScanners Oct. 2 at 12:44 AM
$BCAX reached 17.38, lets go team
0 · Reply
highnihilism
highnihilism Oct. 1 at 6:28 AM
$BSY Bentley Systems Trade Count: 49 | Total $: 23 K | 90-Day Avg $: 277.4 K | Relative: 0.08 | Call $: 9.6 K | Put $: 13.5 K | % Single-Leg: 89% | % Multi-Leg: 11% | % Contingent: – $HDB HDFC Bank Trade Count: 20 | Total $: 9.8 K | 90-Day Avg $: 125.9 K | Relative: 0.08 | Call $: 9.6 K | Put $: 225 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $BCAX Bicara Therapeutics Trade Count: 35 | Total $: 10.7 K | 90-Day Avg $: 6.5 K | Relative: 1.64 | Call $: 9.6 K | Put $: 1.2 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CBRE CBRE Group Trade Count: 33 | Total $: 29.1 K | 90-Day Avg $: 189 K | Relative: 0.15 | Call $: 9.5 K | Put $: 19.5 K | % Single-Leg: 65% | % Multi-Leg: 35% | % Contingent: –
0 · Reply
StockScanners
StockScanners Oct. 1 at 2:15 AM
$BCAX reached 15.83
0 · Reply
highnihilism
highnihilism Sep. 30 at 4:30 PM
$BSY Bentley Systems | Price: 51.98 | % Chg: -0.7% | Trade Count: 49 | Total $: 23 K | 90-Day Avg $: 277.4 K | Relative: 0.08 | Call $: 9.6 K | Put $: 13.5 K | % Single-Leg: 89% | % Multi-Leg: 11% | % Contingent: – $HDB HDFC Bank | Price: 34.14 | % Chg: 0.0% | Trade Count: 20 | Total $: 9.8 K | 90-Day Avg $: 125.9 K | Relative: 0.08 | Call $: 9.6 K | Put $: 225 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $BCAX Bicara Therapeutics | Price: 13.87 | % Chg: +18.4% | Trade Count: 35 | Total $: 10.7 K | 90-Day Avg $: 6.5 K | Relative: 1.64 | Call $: 9.6 K | Put $: 1.2 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CBRE Cbre Group | Price: 158.96 | % Chg: +0.6% | Trade Count: 33 | Total $: 29.1 K | 90-Day Avg $: 189 K | Relative: 0.15 | Call $: 9.5 K | Put $: 19.5 K | % Single-Leg: 65% | % Multi-Leg: 35% | % Contingent: –
0 · Reply
StockScanners
StockScanners Sep. 30 at 1:09 AM
$BCAX keep watch if this holds above 12.80
0 · Reply
100Bandz
100Bandz Sep. 29 at 2:57 PM
$BCAX Trending...
0 · Reply
redistributeW
redistributeW Sep. 29 at 12:00 PM
$BCAX Why is Stocktwits deleting posts and not providing quotes for this company?
1 · Reply
highnihilism
highnihilism Sep. 17 at 11:51 AM
IWM: Russell 2000 → $GBTG Global Business Travel $NIC Nicolet Bankshares $DGII Digi International $HG Hamilton Insurance Group $BCAX Bicara Therapeutics
0 · Reply
GhostTrend
GhostTrend Aug. 23 at 7:05 AM
$BCAX BCA Acquisition Corp is another SPAC with time limitation to find target
1 · Reply
JarvisFlow
JarvisFlow Aug. 19 at 12:00 PM
Piper Sandler has adjusted their stance on Bicara Therapeutics ( $BCAX ), setting the rating to Overweight with a target price of 36.
0 · Reply
Pratik2024
Pratik2024 Jun. 26 at 6:02 PM
$BCAX $CURV $DECK $HNRG $IMMX CURV - PR AF or tomorrow.
0 · Reply
Pratik2024
Pratik2024 Jun. 26 at 3:47 PM
$BCAX $CURV $DECK $HNRG $IMMX CURV (when flying is eminent, better buckle up): 1. The secondary public offering is expected to be closed today, 26 June. 2. The company is buying back shares of $20 million.
0 · Reply
Pratik2024
Pratik2024 Jun. 26 at 2:13 PM
$BCAX $DECK $HNRG $IMMX $CURV CURV is it the bottom to load more?
0 · Reply
Pratik2024
Pratik2024 Jun. 24 at 2:57 PM
$BCAX $DECK $HNRG $IMMX $MWYN $MWYN only 2 million market float and 72% owns by the insiders. How many available for publicly trading? Went to $11 for $4 after IPO’d. Right now, discounted price. Anything can happen.
0 · Reply
Bionoobbb
Bionoobbb Jun. 14 at 4:12 AM
$PDSB $BCAX Bicara Therapeutics 🔹 Target Population: Bicara is targeting patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly those who are HPV-negative. Their lead approach uses BCA101, a bifunctional EGFR/TGF-β inhibitor, in combination with Keytruda, in the first-line setting. 🔹 Current Status: • Like Merus, Bicara’s trials require patients to be PD-1–naïve (i.e., they must not have previously received PD-1 inhibitors). • With Keytruda now moving into perioperative treatment for resectable disease — and given that most of those patients are HPV-negative — many of Bicara’s potential patients will now be treated earlier with Keytruda. • As a result, when the disease recurs, those patients will no longer be eligible for Bicara’s trials. 🔹 Conclusion ❌ This poses a major threat to Bicara’s eligible patient pool, especially since the company is focusing on the HPV-negative segment — the same population that dominates KEYNOTE-689
0 · Reply
Bionoobbb
Bionoobbb Jun. 13 at 2:00 PM
$PDSB $MRUS @DubK FDA has approved $MRK keytruda in neoadjuvant which will reduce the patient pool for MRUS & $BCAX Smaller Patient Pool • Merck’s Keytruda just got approved for (neoadjuvant use) • Since Keytruda is now approved and proven, doctors may choose it over joining a new trial for an experimental drug. • Result: Fewer patients may join Merus’ trial, making it harder for them to prove their drug works or to sell it later.
0 · Reply
Ontherag
Ontherag Jun. 11 at 4:14 PM
$PDSB $BCAX Both going to own frontline R/M HNSCC 🔥
0 · Reply
redistributeW
redistributeW Jun. 4 at 10:32 AM
$BCAX merus doing a stock offering but would rather see Bicara either get acquired or partnership.
1 · Reply
Jimbates22
Jimbates22 Jun. 3 at 4:19 PM
$BCAX looking like a good decision to buy those calls. They had pretty low IV too.
0 · Reply